Tiziana begins phase 1b trial of oral foralumab for Crohn's Disease

Tharakorn/iStock via Getty Images

• Tiziana Life Sciences (NASDAQ:TLSA) began a phase 1b trial to evaluate oral enteric-coated capsules of foralumab in patients with mild-to-moderate Crohn's Disease (CD), a type of inflammatory bowel disease.
• The company said patient enrollment will begin in Q2.
• Tiziana noted that the trial, for the first-ever oral immunotherapy for patients with mild-to-moderately active CD, is expected to be completed by Q4.
• TLSA +4.50% pre-market to $1.16